Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us


Growth of Geriatric Population, Immunodeficiency Disorders to Augment Demand for Intravenous Immunoglobulin Worldwide

Blog Description

Intravenous immunoglobulin (IVIG) is primarily used in the treatment of patients diagnosed with primary and secondary immunodeficiency disorders. They are highly effective in combating infections, apart from treating these disorders. Therefore extensive research is carried out for their development, as newer application areas materialize. 

Browse the full Global Intravenous Immunoglobulin (IVIG) Market Report:

Some of the key growth drivers of the global intravenous immunoglobulin market are: 

  • High incidence of autoimmune disorders such as multiple sclerosis, Kawasaki syndrome, and primary humoral immunodeficiency (PIDD), along with the growing prevalence of cancer, neurological disorders, and diabetes will aid market expansion. Almost 83 out of 100,000 people in the U.S. suffer from primary immunodeficiency, as per the research conducted by Immune Deficiency Foundation (IDF). 
  • The findings of the WHO reveal that the global geriatric population is likely to increase from 524 million in 2010, to 1.5 billion by the end of 2050. The geriatric population is more vulnerable to infectious diseases due to the decreasing efficiency of their immune system. As the aging population worldwide increases substantially, the need for IVIG will also augment. 
  • The increasing healthcare expenditure, government reimbursement programs, and rising per capita incomes of people will not only aid the expansion of the global intravenous immunoglobulin market, but also boost demand for blood plasma products. 

Active Involvement of Government Sectors to Aid Market’s Expansion in North America 

Presently North America is dominating the global scenario, chiefly influenced by the active involvement of the private and government sectors in the research and development projects. The credit for the prominence of this region can be given to the U.S., the largest plasma yielding country in the world. It is evident that this has been one of the strongest growth drivers, apart from the extensive research and development activities and immense spending in healthcare. However, the regions of Europe and Asia Pacific also appear to possess promising opportunities, being the second-most and third-most leading markets, respectively. 

Recently, there has been a rising inclination towards subcutaneous infusion. It has been proven that the therapeutic effectiveness of immunoglobulin administration through subcutaneous route is as effective as intravenous administration. Subcutaneous immunoglobulin can not only be self-administered once a person receives basic training from a health professional, but it is also risk-free. It is performed through the use of a portable infusion pump. Some of the key reasons for the rising popularity of this method are minimal side effects, steady serum levels, home treatment convenience, improved quality of life, and ease of mobility. 

While developed countries have been adopting IVIG for primary immunodeficiency and also off-label indications, developing countries have only recently begun to enter this domain. 

Browse the full Press Release of Global Intravenous Immunoglobulin (IVIG) Market at :

Some of the major companies operating in the global market for intravenous immunoglobulin are China Biologic Products, Inc., Grifols S.A., Octapharma AG,  Baxalta Incorporated, LFB Biomedicaments S.A.,  Sanquin Plasma Products B.V., and CSL Behring LLC. One of the major trends observed is the provision of new payment and therapy assistance programs by numerous market players. For example, ‘My IG Source’, a comprehensive program was launched by the U.K. based Baxalta, provides treatment and prescription related assistance to patients undergoing long-term IG therapy.